Skip to main content
Premium Trial:

Request an Annual Quote

Mitsubishi-Tokyo Makes Equity Investment in Quark Biotech

NEW YORK, Sept. 11 – Quark Biotech said Tuesday that Mitsubishi-Tokyo Pharmaceuticals of Japan has made an equity investment in the company of an undisclosed amount.

Quark and Mitsubishi-Tokyo, a wholly owned subsidiary of Mitsubishi Chemical Corporation, are currently collaborating to develop drug targets for neurodegenerative diseases as well as other disease areas.

"QBI's team, along with its applied genomics technology, will greatly accelerate the drug discovery and development activities of our company," Akihiro Tobe, president of research and development of Mitsubishi-Tokyo said in a statement. 

In addition to the equity investment, Mitsubishi-Tokyo will continue to fund research at QBI and collaborate with QBI scientists. QBI will receive royalties on sales of the products developed from this collaboration, as well as milestone payments. 

Quark Biotech is a functional genomics company based in Cleveland that uses knockout mice technology to validate its findings.

Other investors in Quark include Japan’s  Fugisawa Pharmaceutical and Taisho Pharmaceutical as well as Larry Ellison, CEO of Oracle.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.